2008-09-06 01:02:01 -

- ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that A. Ernest Whiton, its Chief Financial Officer and Vice President of Administration, is entering into a 10b5-1 sales plan for the sale of up to 80,000 shares of ZOLL common stock over an approximate 12-month period. It is expected that Mr. Whiton

will sell approximately 15,000 to 20,000 shares each quarter pursuant to the Plan, depending on market conditions. Sales under the plan will commence in the first quarter of fiscal 2009. The shares to be sold will be acquired upon the exercise of a portion of stock options which were granted to Mr. Whiton over the past several years. This new plan follows 10b5-1 sales plans entered into by Mr. Whiton in September 2006 and September 2007.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia.

Certain statements contained in this press release regarding matters that are not historical facts are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, market conditions affecting trading in ZOLL stock, the market price for ZOLL stock, ZOLL's ability to compete in the resuscitation business; acceptance of its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled "Risk Factors" in ZOLL's Quarterly Report on Form 10-Q, which was filed with the SEC on August 10, 2007.

(C)2007 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation.

ZOLL Medical Corporation
A. Ernest Whiton, +1 978-421-9655
Chief Financial Officer